Immudex ApS
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
CVR 31 34 88 54AnpartsselskabVirumStiftet 2008
The main activities of Immudex are to provide MHC Dextramer® reagents and services for improved cellular immune monitoring to be used in research, clinical development and patient monitoring. The Company has during the fiscal year had the following focus areas: i.
Oplysningerne er hentet 5. november 2026.